A nitric oxide releasing derivative of flurbiprofen inhibits experimental autoimmune encephalomyelitis

Furlan R., Kurne A., Bergami A., Brambilla E., Maucci R., Gasparini L., ...More

JOURNAL OF NEUROIMMUNOLOGY, vol.150, pp.10-19, 2004 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 150
  • Publication Date: 2004
  • Doi Number: 10.1016/j.jneuroim.2004.01.004
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.10-19
  • Hacettepe University Affiliated: No


Nitric oxide (NO)-releasing non-steroidal anti-inflammatory drugs (NSAIDs) have been reported to have a safer profile and additional anti-inflammatory and immuno-modulatory properties compared to parent compounds. Preventive treatment of experimental autoimmune encephalomyelitis (EAE)-induced in C57BL/6 mice by immunization with myelin oligodendrocyte glycoprotein (MOG) peptide 35-55-with the NO-releasing derivative of flurbiprofen HCT1026 delayed disease onset and significantly decreased disease severity. HCT1026 treatment was associated to (i) decreased mRNA levels of pro-inflammatory cytokines, caspase-1, and iNOS in blood cells; (ii) decreased ability of encephalitogenic T cells to proliferate; (iii) reduced number of central nervous system (CNS)-infiltrating T cells; (iv) decreased axonal loss and demyelination; (v) increased CD4(+) CD69(-) CD25(+) regulatory T cells in the spleen. (C) 2004 Elsevier B.V. All rights reserved.